---

🧠 CLOZAPINE - Complete Exam & Viva Masterclass

---

1. INTRODUCTION & HISTORICAL CONTEXT

1. A specific FDA/MHRA approval for treatment-resistant schizophrenia
2. A specific FDA approval for reducing suicidal behaviour in schizophrenia/schizoaffective disorder (based on the InterSePT study)
3. An approved indication for Parkinson's disease psychosis (low doses, 12.5-50 mg/day)

• Monitoring burden (blood tests)
• Side effect fear
• Lack of centralized infrastructure
• Despite evidence: only <10% of TRS patients receive it in most settings
• 34-fold variation across NHS Trusts recorded in UK data

---

2. CHEMISTRY

• Dibenzothiazepine / dibenzodiazepine derivative (tricyclic)
• Chemical formula: C₁₈H₁₉ClN₄; molecular weight 326.8
• IUPAC: 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
• Clozapine-derived SGAs include: olanzapine, quetiapine (being a derivative does NOT translate to similar efficacy)

---

3. PHARMACOKINETICS

• All oral formulations (tablets, oral suspension, orally-dissolving tablets/ODT) are bioequivalent
• Check plasma level 1 week after switching formulations
• IM formulation (25 mg/mL, available in limited countries): 100% bioavailable; IM dose = approximately half oral dose
• Food does NOT significantly affect absorption

• CYP1A2 is the primary enzyme (critically important!)
• Main active metabolite: Norclozapine (N-desmethylclozapine) - 40-80% of clozapine concentration; muscarinic M1 agonist (clozapine itself is M1 antagonist)
• Inactive metabolite: Clozapine-N-oxide (<10% of active moiety, limited CNS penetration due to PGP efflux)
• Mean plasma clozapine:norclozapine ratio = 1.32

• Trough level (12-hour trough): 350 ng/mL minimum for therapeutic response in schizophrenia
• 100 ng/mL is the minimum threshold (Kaplan & Sadock)
• Response correlates with trough clozapine level, NOT combined clozapine+norclozapine
• Toxicity more likely above 600 ng/mL; seizure risk above 600 ng/mL strongly increases

---

4. PHARMACODYNAMICS / MECHANISM OF ACTION

Receptor Binding Profile (Ki values, lower = higher affinity):

1. PET scan data: At therapeutic doses, clozapine occupies only 20-67% of D2 receptors (vs >80% for typical antipsychotics). This "fast dissociation" from D2 is the "hit and run" hypothesis (Kapur & Seeman).
2. Why no EPS/tardive dyskinesia? Low D2 occupancy + high 5-HT₂A antagonism (protects nigrostriatal pathway) + preferential mesolimbic vs nigrostriatal activity
3. Why uniquely effective in TRS? - Not fully explained by monoamine receptor profile alone. Theories include: prefrontal dopaminergic enhancement, glutamatergic modulation (NMDA), network-level effects, anti-inflammatory properties
4. Norclozapine's M1 agonism: Believed to contribute to superior cognition and negative symptom improvement
5. Clozapine-N-oxide: High affinity for PGP efflux transporter → limited CNS penetration → inactive in practice

---

5. INDICATIONS

1. Treatment-resistant schizophrenia - failed ≥2 adequate antipsychotic trials (at least one SGA), each 6-8 weeks at therapeutic dose
2. Suicidal behaviour in schizophrenia/schizoaffective disorder (FDA-approved; InterSePT study)
3. Parkinson's disease psychosis (12.5-50 mg/day; FDA-approved in USA)

• Treatment-resistant mania / bipolar disorder
• Schizoaffective disorder
• Persistent aggression/violence in psychosis
• Tardive dyskinesia (reduces severity)
• Treatment-resistant catatonia (systematic review 2024, PMID 36117082)
• Schizophrenia with persistent suicidality even without TRS
• Borderline personality disorder with psychotic features (limited evidence)
• Intellectual disability with severe behavioural disturbance

---

6. DOSING & FORMULATIONS

Formulations Available:

• Tablets: 25 mg, 50 mg, 100 mg, 200 mg
• Oral suspension: 50 mg/mL
• Orally dissolving tablets (ODT): 12.5 mg, 25 mg, 100 mg (useful for compliance monitoring)
• IM injection: 25 mg/mL (limited countries; not UK-licensed)

UK Brand Names:

• Clozaril® (Novartis) - requires Clozaril Patient Monitoring Service (CPMS)
• Denzapine® (Mylan) - requires Denzapine Monitoring Service (DMS)
• Zaponex® (TEVA) - requires Zaponex Treatment Access System (ZTAS)

Dose Titration (Standard):

---

7. GUIDELINES

NICE (CG178 - Adults / CG155 - Children & Young People)

• Schizophrenia has not responded adequately to sequential trials of at least 2 different antipsychotics (including at least 1 SGA), each at adequate dose for 6-8 weeks with confirmed adherence

• White blood cell (WBC) and ANC monitoring before starting and throughout treatment
• Standard schedule: Weekly for 18 weeks → 2-weekly to 1 year → 4-weekly thereafter (this is the traditional UK schedule)

• ANC alone as the monitoring marker (WBC count no longer required)
• After 1 year: every 12 weeks
• After 2 years: annually
• UK is expected to adopt this updated guidance

IPS (Indian Psychiatric Society) Guidelines on Clozapine:

• Clozapine for TRS after failure of 2 adequate antipsychotic trials
• Baseline investigations: FBC, LFTs, renal function, fasting glucose, lipid profile, ECG, weight/BMI
• Haematological monitoring as per CPMS-equivalent protocol
• Plasma level monitoring recommended
• Emphasis on informed consent and shared decision-making

TRRIP Working Group / Delphi Consensus (Wagner et al., Schizophr Bull 2023, PMID 36943247):

• Defined TRS clearly for clozapine use
• Standardised plasma level monitoring protocol
• Recommended level-based dose optimisation

---

8. ADVERSE EFFECTS

Common (>10%)

Serious / Life-threatening

• Incidence: 0.4% of patients (ANC <0.5×10⁹/L)
• Fatal agranulocytosis: 0.013% (1 in ~8,000)
• Case fatality rate of agranulocytosis: 2.1% (if managed promptly)
• Timing: Mostly within first 18 weeks - highest risk 4-18 weeks
• After 1 year: incidence declines to negligible levels
• Mechanism: Reactive metabolite hypothesis (nitrinium ion); immune-mediated

• Continuous, rapid, catastrophic fall in neutrophils to zero or near-zero
• Prolonged nadir and delayed recovery (4-16 days) unless G-CSF given
• Differentiate from Benign Ethnic Neutropenia (BEN) - common in African/Caribbean/Middle Eastern populations

• Normal: ≥2.0×10⁹/L
• Mild neutropenia: 1.5-2.0×10⁹/L → increase monitoring
• Significant neutropenia: 1.0-1.5×10⁹/L → interrupt, daily monitoring
• Agranulocytosis: <0.5×10⁹/L → STOP clozapine, never rechallenge after confirmed CRLTA

• Myocarditis incidence: ~0.7-1.2% (Australian data)
• Timing: First 4-6 weeks (peak at 2-3 weeks)
• Mechanism: Eosinophilic/hypersensitivity myocarditis; IgE-mediated
• Symptoms: fever, tachycardia, chest pain, dyspnoea
• Investigations: troponin, CRP, ECG, echocardiogram, eosinophil count
• 2026 consensus (Br J Psychiatry, PMID 40452212): Multidisciplinary consensus on prevention, screening and monitoring; rechallenge after myocarditis may be possible in selected cases with careful monitoring
• Risk factors: rapid titration, concomitant sodium valproate
• Rechallenge after myocarditis: controversial but possible in specialist centres per 2026 consensus

• Dose-dependent; strongly associated with levels >600 ng/mL
• Risk ~3-5% overall; higher with rapid titration
• EEG changes (non-specific slowing) in ~10%
• Management: reduce dose; valproate is first-choice prophylaxis/treatment (but note: valproate ↑ clozapine levels slightly and ↑ myocarditis risk with rapid titration)

• Atypical presentation with clozapine (lower rigidity, may have leukocytosis, fever)
• Higher confusion and autonomic instability
• Clozapine-induced fever/leukocytosis can mask NMS

• Rare but recognised; incidence ~1 case per 2,000-3,000 patients
• Dose-independent; early onset (first months)
• Mechanism: increased platelet aggregation, sedation, obesity

• Weight gain average 4-10 kg in first year
• New-onset T2DM: 3-4 fold increased risk
• Dyslipidaemia: TG elevation prominent

• Severe constipation can progress to fatal paralytic ileus
• Leading cause of clozapine-associated death other than agranulocytosis in some series

Rare / Unusual / High-yield for Viva

---

9. CONTRAINDICATIONS

• History of clozapine-induced agranulocytosis or severe neutropenia (CRLTA)
• Bone marrow disorders
• Active severe liver disease with hepatic failure
• Severe CNS depression or coma
• Paralytic ileus
• Uncontrolled epilepsy
• Hypersensitivity to clozapine

• Carbamazepine (additive bone marrow suppression)
• Alcohol dependence (CNS depression)
• History of circulatory collapse
• Prostatic hypertrophy (anticholinergic)

---

10. MONITORING PROTOCOL (Pre-treatment and Ongoing)

Pre-treatment investigations:

• FBC (including ANC) - baseline
• LFTs
• Renal function (U&E, creatinine)
• Fasting glucose and HbA1c
• Fasting lipids
• ECG (QTc)
• Weight, BMI, waist circumference
• Blood pressure (lying and standing)
• Troponin and CRP (myocarditis screening - becoming standard practice)
• Echocardiogram if clinically indicated

Blood monitoring schedule (current UK standard):

• Weeks 1-18: Weekly FBC/ANC
• Weeks 19-52: Every 2 weeks
• After 52 weeks: Every 4 weeks (monthly)

• ANC only (not WBC)
• After 1 year: Every 12 weeks
• After 2 years: Annually

Ongoing monitoring (Maudsley 15th Ed):

• Metabolic monitoring: weight, glucose, lipids - at baseline, 3 months, annually
• BP: each visit for first 6 months, then annually
• ECG: at baseline; repeat if symptoms
• Troponin + CRP: at baseline, then weekly for first 4-6 weeks (myocarditis screen)
• Plasma clozapine level: at steady state, after dose changes, after interacting drug changes

---

11. DRUG INTERACTIONS (High-yield)

---

12. TOXICITY / OVERDOSE

1. Excessive sedation, somnolence
2. Hypersalivation, delirium
3. Tachycardia, hypotension
4. Seizures
5. Respiratory depression
6. Coma
7. Cardiovascular collapse

• Therapeutic: 350-600 ng/mL
• Subtherapeutic: <350 ng/mL
• Toxic: >1,000 ng/mL (seizures very likely)
• Fatal: >2,500 ng/mL reported

• Supportive (ABC, ICU)
• No specific antidote
• Activated charcoal if within 1-2 hours (if airway protected)
• Seizures: benzodiazepines (IV lorazepam), then levetiracetam
• Hypotension: IV fluids, noradrenaline (NOT adrenaline - risks paradoxical hypotension via α₁ blockade); avoid dopamine
• Monitor ECG, respiratory status
• Note: dialysis NOT effective (high protein binding)

---

13. SPECIAL POPULATIONS

• Start at 6.25-12.5 mg/day; slower titration
• More vulnerable to orthostasis, sedation, falls, constipation
• Useful in Parkinson's disease psychosis at low doses

• Category C; crosses placenta
• Limited data; weigh risk of untreated psychosis vs neonatal complications
• Neonatal withdrawal/adaptation syndrome reported
• Monitoring: neonatal ANC recommended

• NICE CG155: After failure of ≥2 antipsychotics (6-8 weeks each)
• Plasma monitoring more important (different pharmacokinetics)
• Lower starting doses; very gradual titration

• Start no higher than 25 mg QHS
• Slower titration
• Daily orthostatic BP monitoring for first 2 weeks

• Common in people of African, Caribbean, Middle Eastern, some Mediterranean descent
• Lower normal ANC thresholds apply
• Genetic testing recommended (HLA typing)
• ANC thresholds in BEN: use adjusted lower limits per established protocols

---

14. CLOZAPINE AUGMENTATION STRATEGIES

1. Amisulpride - best evidence (D2 partial agonist; also reduces sialorrhea as side benefit)
2. Aripiprazole - useful; also reduces metabolic side effects, may reduce prolactin
3. Sulpiride - traditional augmentation
4. Lamotrigine - for negative symptoms; reduces seizure risk (but watch Stevens-Johnson with valproate)
5. ECT - evidence for clozapine augmentation with ECT in TRS
6. Antidepressants - 2025 Lancet Psychiatry (PMID 40675714): real-world European cohort data shows clozapine + antidepressants effective; augmentation with SSRIs/SNRIs/mirtazapine
7. Glycine/D-serine/sarcosine - experimental; targets glutamate pathway

---

15. RECENT ADVANCES & KEY TRIALS (2023-2026)

Landmark trial:

• Efficacy of clozapine vs SGAs in TRS: systematic review and individual patient data meta-analysis
• Confirmed clozapine's superiority over other SGAs in TRS

• Meta-analysis suggests high-dose olanzapine may partially approximate clozapine in TRS but does NOT replace it

• European nationwide cohorts; clozapine + antidepressants shows real-world effectiveness

• Multidisciplinary consensus: standardised troponin and CRP monitoring protocol
• Rechallenge after myocarditis is possible in selected patients under strict monitoring

• Clarifies rare but real risk of clozapine-associated pericarditis

• Clozapine-associated sterile inflammation (fever, ↑CRP, eosinophilia) clarified

• Major regulatory change - removes mandatory centralised monitoring registry
• ANC monitoring remains mandatory per prescribing guidelines

• ANC-only monitoring
• Extended monitoring intervals (12-weekly after 1 year; annual after 2 years)

---

16. VIVA PEARLS & HIGH-YIELD FACTS

Low D2 occupancy ("fast dissociation"), high 5-HT₂A antagonism, D4 blockade, modulation of prefrontal dopamine, anti-inflammatory properties, glutamatergic modulation - mechanism not fully established

Only 20-67% D2 occupancy (vs 80%+ for typicals); preferential mesolimbic vs nigrostriatal activity; high 5-HT₂A antagonism protects nigrostriatal pathway

Trough ≥350 ng/mL required for adequate trial; no clear upper therapeutic limit but toxicity increases above 600 ng/mL

First 18 weeks; highest risk 4-18 weeks; negligible after 1 year

Restart at 12.5 mg once/twice daily; risk of cardiorespiratory collapse at previous dose

Benign Ethnic Neutropenia - lower baseline ANC in people of African/Caribbean/Middle Eastern descent; NOT clozapine-related; use adjusted thresholds; failure to recognise leads to wrongful clozapine denial

Carbamazepine - double bone marrow suppression + ↓ clozapine levels

International Suicide Prevention Trial; showed clozapine superior to olanzapine in reducing suicidal behaviour → basis for FDA approval of suicide indication

Clozapine (12.5-50 mg/day); quetiapine has less evidence but is used due to easier monitoring

1. Constipation/ileus (often underappreciated), 2. Agranulocytosis, 3. Myocarditis, 4. VTE, 5. Seizures

Mean ratio 1.32; ratio distorted by CYP1A2 inducers/inhibitors (smoking, fluvoxamine etc); clinically useful for assessing adherence and drug interactions

Growing evidence - systematic review 2024 (Schizophr Res) supports use in refractory catatonia

Smoking induces CYP1A2 → reduces levels 50%+ → smoker needs higher doses; stopping smoking (e.g. in hospital) → levels rise → toxicity risk → must monitor and reduce dose

---

17. SUMMARY COMPARISON TABLE (Viva-ready)

---

---

---

📖 Clozapine Handbook - Additional & Deeper Content

---

1. THE KANE 1988 TRIAL - EXACT CRITERIA (Box 1.1)

1. At least three periods of treatment in the preceding 5 years with antipsychotics from at least two different chemical classes at doses ≥1,000 mg/day chlorpromazine equivalent for 6 weeks each, without significant symptomatic relief.
2. No period of good functioning within the preceding 5 years.
3. Prospective failure of a high-dose typical antipsychotic: haloperidol up to 60 mg/day + benztropine 6 mg/day. Response was defined as ≥20% decrease in BPRS total score PLUS either a CGI severity rating of mildly ill (≤3) OR a post-treatment BPRS score ≤35.

• Fewer than 2% met response criteria in the prospective haloperidol arm (mean dose 61 mg/day)
• 80% were nonresponders; 18% intolerant of high-dose haloperidol
• Final response: 4% chlorpromazine vs 30% clozapine in n=268 patients over 6 weeks
• With longer-term studies incorporating plasma level guidance: response rates rise to 40-60%

---

2. CLOZAPINE AND MORTALITY (Chapter 1)

• A 2018 meta-analysis of 24 long-term mortality studies found mortality rate ratios 44% lower in patients continuously treated with clozapine (vs. other antipsychotics)
• The mortality benefit is ONLY present if the patient continues on clozapine - not in "ever used" clozapine patients
• Danish data: mortality was highest in periods after clozapine discontinuation (HR: 2.65, 95% CI 1.47-4.78)
• London cohort study (14,754 patients, 2007-2011): clozapine associated with lower mortality even after controlling for confounders including clinical monitoring intensity (adjusted HR 0.4; 95% CI 0.2-0.7; p=0.001)
• Finnish 11-year study: clozapine markedly reduces suicide-related mortality; no pronounced difference in ischemic heart disease mortality vs. other antipsychotics

---

3. IMPACT OF DELAYS IN COMMENCING CLOZAPINE (Chapter 1)

• Delaying clozapine reduces likelihood of response (Figure 1.1 - critical concept)
• Yoshimura et al. (2017): there is a "critical treatment window" for clozapine - the longer the delay after meeting TRS criteria, the lower the response rate
• Patients in low-clozapine-use counties were nearly twice as likely to not receive clozapine as those in high-use counties
• 34-fold variation across NHS Trusts in UK (2002 data)
• Despite 20-30% of schizophrenia patients being TRS, only 6 of 50 US states report >10% of schizophrenia patients on clozapine

• Web-based patient education modules (e.g. NY State "Considering Clozapine")
• Clozapine clinics with dedicated nurse coordinators
• Patient and family testimonials
• Addressing benign ethnic neutropenia thresholds
• Centralised clozapine coordination services

---

4. CLOZAPINE FOR AGGRESSION (Chapter 1, Table 1.5) - UNDERAPPRECIATED INDICATION

• Krakowski et al. 2006 (most important): 12-week RCT in physically assaultive inpatients; clozapine > olanzapine for total MOAS-30 score, physical aggression against people, verbal aggression, physical aggression against objects. Clozapine > haloperidol for all aggression subscales.
• Citrome et al. 2001/Volavka et al. 2002/2004: 14-week RCT; clozapine superior to haloperidol for reducing aggression severity; risperidone and olanzapine had less antiaggressive efficacy in aggressive patients - opposite was true for clozapine
• Clozapine reduces aggression by independent mechanisms beyond psychosis reduction (separate antiagressive effect)
• Key fact: Clozapine's antiagressive effect exceeds that of other SGAs even in non-TRS-defined patients

---

5. CLOZAPINE FOR TREATMENT-RESISTANT MANIA (Box 1.3)

1. Adjunctive clozapine is equally effective in treatment-resistant non-psychotic bipolar patients and those with schizoaffective disorder, bipolar type
2. Associated with reduced hospital admissions, number of hospital days, hospital visits for self-harm/intentional overdose, and total psychotropic medication use (drug rationalisation)
3. Mean endpoint doses for bipolar I patients in long-term (≥1 year) studies: 234-305 mg/day (much lower than schizophrenia doses)
4. Higher doses typical of schizophrenia spectrum disorders are needed for schizoaffective disorder, bipolar type
5. Rapid titration in bipolar inpatients reduced time to discharge readiness by <4 days only
6. Forced titration (25 mg/day advance to 550 mg/day): only 14 of 22 manic patients completed 12 weeks (tolerability is a major issue)

---

6. PARKINSON'S DISEASE PSYCHOSIS (PDP) - Full Chapter Detail

• PD is a multisystem disease: motor symptoms from nigrostriatal dopamine loss; cognitive impairment from cholinergic loss; depression from noradrenergic loss
• Previously called "levodopa psychosis" - but this is a misconception
• True mechanism: loss of serotonergic midbrain dorsal raphe neurons from Lewy body accumulation → upregulation and supersensitivity of postsynaptic 5-HT₂A receptors (confirmed by neuroimaging)
• This explains why clozapine (high 5-HT₂A antagonism, minimal D2 blockade) is ideal - it does not worsen motor symptoms

• PD worldwide prevalence >7 million

• 50% will develop PDP; rises to 75% in PD with dementia

• PDP is associated with increased caregiver burden, increased nursing home placement, and increased mortality

• Only FDA-approved drug for PDP (in USA) at the time of the Handbook
• Effective at very low doses 12.5-50 mg/day (nonsmokers; smokers may need 25-75 mg/day)
• The PPSG (Parkinson Study Group) conducted the first double-blind, placebo-controlled RCT in PDP (1999)
• Clozapine 6.25-50 mg/day significantly reduced hallucinations without worsening motor symptoms
• A French multicentre trial replicated these findings
• Pimavanserin (5-HT₂A inverse agonist) is now FDA-approved for PDP (2016) but clozapine preceded it

• Lower ANC thresholds used by many neurologists due to dementia risk from infection
• Particularly susceptible to sedation and falls - start with 6.25 mg at bedtime
• Metabolic monitoring especially important

---

7. PLASMA LEVELS - DETAILED SECTION (Chapter 5)

• Non-responders without dose-limiting adverse effects: explore levels up to 1,000 ng/mL (3,057 nmol/L)
• Very few patients will respond at levels >1,000 ng/mL (the "point of futility")
• Rare patients may tolerate and respond above 1,000 ng/mL

1. Plasma clozapine levels (NOT combined clozapine+norclozapine) best correlate with efficacy
2. Serum vs plasma: serum levels on average only 3% higher than haematocrit-corrected plasma levels - both acceptable
3. Primary use of norclozapine levels: tracking CYP1A2 activity
4. If ratio is low (clozapine:norclozapine <1.0): suggests CYP1A2 induction (e.g. smoking, rifampicin)
5. If ratio is high (>2.0): suggests CYP1A2 inhibition (e.g. fluvoxamine, infection/inflammation, caffeine)

• Obtain initial level early in therapy to establish individual metabolic pattern
• Many clinicians obtain first level at a round dose like 100 mg or 200 mg QHS during titration
• On a level above 350 ng/mL, wait at least 3 weeks before declaring non-response
• D2 and 5-HT₂A occupancy data: predicted occupancy at 200-400 mg/day shows that 5-HT₂A occupancy is nearly complete at lower doses, while D2 occupancy remains low (Figures 5.2 and 5.3 in the book)

---

8. TITRATION - DETAILED TABLES (Chapter 3)

1. "Standard" titration must be individualised - prolonged titration over many months must be avoided, but schedules must be adjusted
2. Aggressive management of early ADRs (constipation, sialorrhea, sedation, orthostasis) is essential to prevent premature discontinuation
3. Timely tapering of concurrent medications whose adverse effects overlap with clozapine

• Day 1: 12.5 mg at night
• Day 2: 25 mg at night
• Day 3: 25 mg twice daily
• Advancing 25-50 mg/day as tolerated
• (Smokers: advance dose 33% faster due to 50% lower levels)

• Advance every 3-4 days rather than daily

• Vital signs (BP lying and standing, HR) at baseline and after each dose increase
• Daily BP monitoring for orthostasis
• Temperature daily for first 4-6 weeks (myocarditis/fever detection)
• Weekly CBC/ANC as per monitoring system
• Troponin + CRP at baseline and weekly for first 4-6 weeks

---

9. POSITIVE SYMPTOM NON-RESPONSE / AUGMENTATION (Chapter 2)

• Confirm adequate plasma level (≥350 ng/mL) and adequate trial duration before declaring non-response
• Amisulpride has the best evidence for augmentation (also reduces sialorrhea as a bonus)
• Risperidone: some evidence but adds D2 burden; may worsen EPS
• Aripiprazole: useful for metabolic side effects
• Before adding any antipsychotic, rule out: non-adherence, subtherapeutic level, substance use, sleep disorder, medical comorbidity

• ECT is more effective when combined with clozapine than with other antipsychotics (retrospective data)
• Prolonged seizure: <5%; Delirium: <5% when combined with clozapine
• Post-treatment hypertension noted in one Indian study (17%) - must manage pre-ECT tachycardia
• Mild cognitive impairment ~10% - not persistent; severe impairment not reported
• Most papers use bilateral electrode placement for schizophrenia; no consensus on bitemporal vs bifrontal
• Mean number of treatments in controlled trial: 15 over 8 weeks; case series mean: 14 treatments; some respond in as few as 5 treatments
• Sustained response often noted; some need maintenance ECT
• Superiority of ECT+clozapine over ECT+other antipsychotics confirmed in large retrospective study (post-treatment hospital days)

---

10. METABOLIC EFFECTS - CHAPTER 11 (Block 2)

• Nearly all clozapine-treated patients will manifest one or more metabolic adverse effects; weight gain occurs very early
• Two evidence-based treatments that should be started at the same time as clozapine: 1) Metformin and 2) Exercise + dietary counselling
• Metabolic adverse effects are generally never a reason to discontinue clozapine
• Naturalistic data (96 patients, 21-year follow-up, mean clozapine use 13 years): elevated cardiovascular risk during first 10 years, with slight decline after first decade

• Most evidence-based pharmacological intervention for clozapine-related weight gain
• Should be started prophylactically at clozapine initiation
• Also improves insulin sensitivity, reduces diabetes risk

• Adding aripiprazole to clozapine can reduce weight and improve metabolic parameters
• Also reduces prolactin (clozapine itself has variable prolactin effects)

• Smoking cessation (a good thing) while on clozapine causes CYP1A2 de-induction → plasma levels rise 50%+ → must reduce clozapine dose by 30-50% after smoking cessation
• Varenicline has evidence for smoking cessation in schizophrenia (Evins et al., JAMA 2014)
• NRT also used; bupropion lowers seizure threshold (caution)
• Physical activity must be tracked as a "vital sign"

---

11. FEVER, MYOCARDITIS, INTERSTITIAL NEPHRITIS, DRESS, SEROSITIS, CARDIOMYOPATHY - Chapter 12 (Block 2)

Fever

• Occurs in approximately 20% of patients during first 8 weeks
• Does NOT by itself mandate permanent clozapine discontinuation
• Work-up during first 60 days: troponin I/T, CRP, BUN/creatinine, urinalysis, FBC, temperature
• Clozapine may be held temporarily during fever work-up
• After 90 days of treatment: fever work-up focuses on common infections and severe neutropenia; clozapine need not be held unless severe neutropenia confirmed

Myocarditis (far deeper than previously covered)

• Incidence: 0.1-3.0% (Australian data 3%; likely underdiagnosed elsewhere)
• Mechanism: hypersensitivity reaction involving increased cytokines with eosinophilic myocardial infiltrates (found at autopsy)
• History: first recognised in 1980 case reports; landmark 1999 Lancet review of 15 Australian cases led to package insert warning
• Onset: first 6 weeks (with rare exceptions); peak at 2-3 weeks
• 20% of cases may NOT have fever - diagnosis can be made on troponin/CRP alone
• Troponin I/T >2x ULN in >90% of myocarditis cases
• 7% of cases with left ventricular impairment on echo will NOT have abnormal troponin but WILL have CRP >100 mg/L - both must be ordered
• Eosinophil count and ECG: less sensitive and less specific than troponin + CRP
• Risk factors for myocarditis: rapid titration; concomitant sodium valproate

Interstitial Nephritis

• Less common than myocarditis; onset typically during first 60 days
• Rechallenge after interstitial nephritis: extremely risky - one case redeveloped nephritis within 2 days of resuming clozapine; second case within 4 days despite 4-year gap
• Unlike myocarditis, no successful rechallenge cases in the literature
• Patients with interstitial nephritis are NOT candidates for rechallenge

DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)

• Immune-mediated T-cell stimulation → eosinophil activation → end-organ cytotoxicity (pancreatitis, hepatitis, nephritis, myocarditis)
• General population incidence: 0.4 per 100,000; but mortality up to 10%
• Eosinophilia (>700/mm³) was 1% in early clozapine trials - only ONE component of DRESS criteria
• Onset: 2-6 weeks after drug initiation
• Only 5 known clozapine DRESS cases in literature - exceedingly rare
• Compare: divalproex (7 cases), carbamazepine (33 cases), lamotrigine (17 cases) as psychiatric DRESS causes
• Features (from 2016 review of 55 psychotropic DRESS cases): fever (most common), maculopapular rash, elevated LFTs, lymphadenopathy, facial edema, eosinophilia
• Diagnosis: RegiSCAR scoring system - "definite" = score ≥5
• Treatment: immediate cessation, ICU, corticosteroids, immunomodulators; manage cholinergic rebound
• NOT candidates for rechallenge

Serositis

• Includes pleuritis, pericarditis, peritonitis
• Less common than myocarditis; onset also during first 60 days
• Associated with the same eosinophilic/hypersensitivity mechanism

Cardiomyopathy

• Distinct from myocarditis: occurs after many months or years of clozapine treatment
• Symptoms: fatigue (without recent medication changes), leg swelling, palpitations, shortness of breath
• Box 12.4 - Considerations in Cardiomyopathy:
  • If clozapine withdrawal fails to improve LVEF → ethical dilemma: is clozapine still net beneficial?
  • Some patients may remain on clozapine with cardiomyopathy under close cardiology supervision
  • Decision must be made collaboratively with patient, family, psychiatrist, and cardiologist

---

12. SIALORRHEA - Chapter 9 (Detailed Mechanisms)

• Constipation: caused by clozapine's muscarinic ANTAGONISM (M3)
• Sialorrhea: caused by norclozapine's muscarinic AGONISM at M1 (norclozapine has lower Ki than clozapine at M1 but HIGHER intrinsic agonist activity - especially M1)
• These are therefore opposite mechanisms from the same drug - explains why treating one may worsen the other
• Pirenzepine (relatively selective M1 antagonist) is effective for sialorrhea - confirms M1 agonism mechanism
• Alpha-2 adrenergic effects also contribute to sialorrhea

1. Reduce clozapine dose if possible
2. Educate patient - it often improves after the first 3-4 months
3. Topical agents preferred over systemic anticholinergics (avoid systemic agents: worsen constipation and cognition)
4. Assessment scales: Drooling Rating Scale (DRS), Drooling Impact Scale, Visual Analogue Scale

• Atropine 1% ophthalmic solution sublingually: 1-2 drops (0.5-1 mg) up to TID - cheap, effective, topical
• Ipratropium 0.03-0.06% nasal spray: 1-2 sprays to buccal mucosa TID (topical, minimal systemic absorption)
• Pirenzepine (M1 selective): where available; 25-50 mg BID
• Glycopyrrolate: peripheral anticholinergic, does not cross BBB - safer for cognition; however does worsen constipation
  • Box 9.2 warnings: check for urinary retention, constipation before prescribing; avoid in elderly
• Scopolamine (hyoscine) patch: transdermal; worn behind ear
• Amisulpride: 400-800 mg/day has been shown to reduce sialorrhea (via alpha-2 antagonism increasing sialorrhea → amisulpride blocks D2/D3 and may help via other mechanisms; also reduces clozapine partial non-response)

---

13. SEIZURES - Chapter 10 (Deeper Detail)

• Tonic-clonic (most recognised): reported in literature reviews
• Myoclonic: common and often precedes tonic-clonic; knee-buckling is characteristic presentation
• Atonic (drop attacks)
• Complex partial
• Absence
• EEG abnormalities without clinical seizures: not uncommon; routine EEG monitoring NOT recommended

1. Relative seizure risk vs. other antipsychotics? (Not clearly established)
2. Does rapid titration increase seizure risk? (Uncertain)
3. Is there a well-defined dose/plasma level threshold? (No clear threshold - seizures occur even below 300 ng/mL)

1. Early dose adjustments should be based on tolerability (not seizure prevention) - no clear titration-seizure relationship
2. Routine EEG monitoring not recommended - only when clinical suspicion
3. Patients needing greater efficacy should NOT be deprived of levels up to 1,000 ng/mL due to seizure fear
4. Divalproex (sodium valproate) is the anticonvulsant of choice for clozapine-related tonic-clonic, myoclonic and atonic seizures
5. Due to risks of divalproex (neutropenia, thrombocytopenia, weight gain, hyperammonaemia) - do NOT use prophylactically; only for documented seizures or high-risk patients
6. Lamotrigine is second choice (if valproate not tolerated) - watch for Stevens-Johnson syndrome (especially with concurrent valproate - requires very slow titration)

---

14. ELDERLY PATIENTS - Chapter 15 (Detailed)

• Mean dose: 264 ± 110 mg/day (range 25-700 mg/day)
• Well tolerated - no patients stopped due to adverse effects
• Psychiatric hospitalisation rates significantly lower in the 5-year post-clozapine period vs. 5-year pre-clozapine period (0.41 vs. 3.8; p<0.001)
• Mortality in clozapine cohort = mortality in non-clozapine elderly schizophrenia patients at the same clinic

• Median dose: 300 mg/day (ages 65-70); 200 mg/day (age 75+)
• Metabolic ratio (clozapine:norclozapine) = 1.8 in elderly (vs. 1.32 in younger adults) - slower CYP1A2 with age
• Plasma level increases ~3% for each 10 kg decrease in body weight from cohort mean of 74 kg
• Some elderly patients remain stable at plasma levels BELOW the 350 ng/mL threshold

• Get plasma level at 150 mg/day; many elderly may respond below 350 ng/mL

• H1 and muscarinic antagonism → sedation, falls, confusion
• Alpha-1 antagonism → orthostasis → falls
• Anticholinergic effects → constipation (more dangerous in elderly)
• Tachycardia → risk in those with pre-existing cardiac disease

---

15. PREGNANCY AND LACTATION - Chapter 15

• 1,341,715 pregnancies in US Medicaid from 3 months before LMP through ≥1 month post-delivery
• 9,258 pregnancies with atypical antipsychotic + 733 with typical antipsychotic in first trimester
• Absolute risk of major congenital malformations per 1,000 live births:
  • Typical antipsychotics: 38.2 (95% CI 26.6-54.7)
  • Atypical antipsychotics: 44.5 (95% CI 40.5-48.9)
  • Untreated women: 32.7 (95% CI 32.4-33.0)
• In the fully adjusted analysis: no increased relative risk for major congenital malformations with antipsychotic exposure
• The unadjusted higher rates reflect confounding by indication (sicker mothers, smokers, substance users)

1. No evidence of increased risk for major congenital malformations from clozapine specifically
2. Neonatal adaptation syndrome: neonates exposed in third trimester may show extrapyramidal signs, jitteriness, tremors - typically resolves within days/weeks
3. Clozapine crosses the placenta; passes into breast milk
4. Gestational diabetes risk is increased - monitor closely
5. Clozapine levels may drop during pregnancy (increased CYP1A2 activity during pregnancy, especially in third trimester) - may need dose increase
6. Post-partum: CYP1A2 activity returns to baseline → levels rise → dose may need reduction
7. Neonatal ANC monitoring recommended
8. Breastfeeding: generally not recommended due to clozapine in breast milk; infant exposure to ~20% of maternal dose; risks of sedation, agranulocytosis in infant

---

16. INTELLECTUAL DISABILITY - Chapter 15

1. Start no higher than 25 mg QHS; slower titration recommended
2. Minimise sedation and orthostasis - these can cause falls and unpredictable behaviour
3. Daily orthostatic BP monitoring for first 2 weeks and after dose increases
4. Daily temperature for first 4 weeks
5. Weekly ANC as per standard protocol
6. Obtain plasma level early to establish individual metabolic pattern
7. Titrate to response using plasma levels, not just dose
8. Communication difficulties may delay recognition of adverse effects - involve carers

---

17. CLOZAPINE DISCONTINUATION AND CHOLINERGIC REBOUND (Chapter 4)

• Clozapine has potent muscarinic antagonist properties
• Abrupt discontinuation → cholinergic rebound: profuse diaphoresis, nausea, vomiting, diarrhoea, headache, psychosis, agitation
• Onset: within 24-48 hours of stopping
• Management: gradual taper if clinically possible; restart clozapine if severe
• If clozapine must be stopped urgently: consider anticholinergic cover (e.g. benztropine) during transition

• If switching to another antipsychotic: overlap and taper
• Cross-titration preferred to abrupt switch
• Patients who were stable on clozapine for years may decompensate rapidly and severely after discontinuation
• Rebound psychosis after clozapine discontinuation is often more severe than pre-clozapine psychosis

---

18. PLASMA LEVEL MONITORING TABLES (Chapter 5, Tables 5.7/5.8)

---

19. SUICIDALITY - Key Handbook Details (Chapter 1)

• InterSePT (International Suicide Prevention Trial): clozapine vs olanzapine in 980 patients at high risk for suicidality; clozapine significantly reduced risk of suicide attempts and hospitalisation to prevent suicides vs. olanzapine
• Effect was independent of antipsychotic efficacy - a direct anti-suicidal effect
• Effect extends to non-TRS patients - suicidality is an indication for clozapine even without treatment resistance
• Adherence data: patients with lower medication possession ratios had 2x higher risk for emergency room visits and 2.5x greater risk for hospitalisation vs. adherent clozapine patients

---

20. BINDING PROFILE TABLE (Table 5.5) - Complete Data

• H₁: clozapine has extremely high affinity (Ki 0.32 nM) - highest of the receptors listed; hence profound sedation and weight gain
• M₁: clozapine antagonist (Ki 6.17) but norclozapine is an agonist (despite higher Ki, has higher intrinsic activity) - the paradox explained
• 5-HT₁A: norclozapine has much higher affinity (Ki 13.9) than clozapine (123.7) - norclozapine contributes more to 5-HT₁A partial agonism → antidepressant/anxiolytic effects
• 5-HT₂C: norclozapine (15.9) has higher affinity than clozapine (39.8) → norclozapine contributes more to weight gain/metabolic effects via 5-HT₂C

---

21. UNIQUE HANDBOOK CLINICAL PEARLS

1. "Standard clozapine titration is a myth" - the book explicitly states this; every titration must be individualised
2. Seven cigarettes/day is sufficient to fully induce CYP1A2
3. Clozapine-N-oxide has high affinity for PGP efflux transporter - this is why it does NOT penetrate the CNS effectively despite high receptor affinity in vitro
4. Myocarditis was recognised earlier than agranulocytosis in chronological history (1980 case reports), but agranulocytosis received more regulatory attention first (1975)
5. Clozapine is the only antipsychotic studied in PDP in a double-blind, placebo-controlled trial that showed efficacy without worsening motor function
6. The prospective arm of the Kane study (high-dose haloperidol before randomisation) is what makes it definitively different from other TRS trials - it rules out pseudoresistance
7. Clozapine levels in non-smokers are 50% higher than smokers for any given dose - hence when a patient stops smoking in hospital, their levels can rise dramatically
8. DRESS: only 5 clozapine cases ever reported in literature - if you see a case, it will be written up. The key features are onset at 2-6 weeks, RegiSCAR score ≥5, and mortality risk up to 10%
9. Cardiomyopathy vs Myocarditis: myocarditis = first 6 weeks, acute, eosinophilic; cardiomyopathy = months to years later, insidious, often seen as fatigue + oedema
10. ECT + clozapine: the combination is SAFER than feared (prolonged seizure <5%, delirium <5%, no persistent cognitive effects) - bilateral placement most used in schizophrenia

---

---